Medicinal chemistry – Page 64
-
Business
EPA focuses on five chemicals
Risk assessments for five chemicals put out for public consultation
-
Business
Illumina investment push
$450 million deal for privately owned US firm Verinata Health, which makes chromosomal tests
-
Business
TB drug milestone for bedaquiline
First TB drug with a new mechanism of action for 40 years wins approval
-
FeatureMaking pain history
From ancient folk remedy to the wonder drug of the early industrial age and beyond. Mike Sutton traces the remarkable history of aspirin
-
Business
Return on drug R&D dropping
The pharma industry is getting less and less return on investment in R&D but trend seems to be bottoming out
-
Business
Drug R&D costs rising
Review from UK consultancy suggests ten-fold increase in per medicine R&D costs over last 30 years
-
OpinionFull disclosure?
The pharma industry should be more open with its trial data, says Derek Lowe
-
Business
Roche and the Tamiflu data
Company position on access to data for antiviral Tamiflu (oseltamivir) tablets could be softening
-
CareersNobel signals for new drugs
Sarah Houlton talks to a company that’s capitalising on the chemistry of communication
-
News
GSK pledge on trials transparency
Pharma giant tackles critics by announcing that it will publish all clinical trials data regardless of the result
-
Business
Bayer and Evotec team up on endometriosis
German collaboration aims to develop three drug candidates in five years
-
OpinionColour and controversy
Bob Hefford considers the spotted past and uncertain future of the chemicals that built the hair dye industry
-
NewsChinese drug makers accused of using ‘gutter oil’
Oil reclaimed from drains may have been used to make an antibiotic intermediate
-
FeatureFood with a function
Compounds normally thought of as medicines are being added to food. Elinor Hughes looks at the scientific and regulatory challenges facing these nutraceuticals.
-
Business
Alzheimer's drug flops in Phase III
Solanezumab from Eli Lilly missed the cognitive and functional primary endpoints of the trials
-
OpinionMonopoly money
Dean Baker says it’s time to start talking seriously about the way in which pharma is funded
-
OpinionProtecting patients at all costs
Suffering stagnant output, and beset by patent expiries and spiralling costs, drug discovery is in poor health. Simon Campbell prescribes a remedy
-
FeatureFast, flexible and flourishing
Paul Workman’s experiences in big pharma, academia and biotech gave him the tools to develop new drugs and spin out successful companies. Sarah Houlton profiles the 2012 Chemistry World entrepreneur of the year
-
FeatureThe latent threat of tuberculosis
Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease
-
PodcastChloral hydrate
Dubbed the 'Mickey Finn', this week's compound has uses in medicine and manipulation